NCT04765436View on ClinicalTrials.gov

PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions
Covid19 Vaccine
Interventions
BIOLOGICAL

PTX-COVID19-B

Sterile solution for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (1)

M9W 4L6

Manna Research, Toronto

All Listed Sponsors
lead

Providence Therapeutics Holdings Inc.

INDUSTRY

NCT04765436 - PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 | Biotech Hunter | Biotech Hunter